 David Arciniegas
Concepts (406)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 40 | 2023 | 451 | 7.940 |
Why?
| | Cognition Disorders | 28 | 2016 | 475 | 3.810 |
Why?
| | Brain Injuries, Traumatic | 12 | 2023 | 301 | 2.500 |
Why?
| | Neuropsychological Tests | 31 | 2023 | 919 | 2.210 |
Why?
| | Bipolar Disorder | 11 | 2023 | 208 | 2.160 |
Why?
| | Neuropsychiatry | 6 | 2020 | 15 | 2.100 |
Why?
| | Neurosciences | 3 | 2017 | 20 | 1.560 |
Why?
| | Memory Disorders | 7 | 2023 | 155 | 1.540 |
Why?
| | Mental Disorders | 18 | 2014 | 902 | 1.520 |
Why?
| | Depressive Disorder, Major | 6 | 2023 | 304 | 1.300 |
Why?
| | Crying | 6 | 2014 | 14 | 1.150 |
Why?
| | Brain | 21 | 2023 | 2370 | 1.110 |
Why?
| | Mood Disorders | 6 | 2023 | 117 | 1.110 |
Why?
| | Consciousness Disorders | 5 | 2023 | 19 | 1.090 |
Why?
| | Affective Symptoms | 5 | 2014 | 49 | 1.040 |
Why?
| | Frontotemporal Dementia | 2 | 2023 | 20 | 1.010 |
Why?
| | Psychotic Disorders | 5 | 2015 | 123 | 0.990 |
Why?
| | Aggression | 4 | 2014 | 185 | 0.960 |
Why?
| | Laughter | 5 | 2014 | 8 | 0.950 |
Why?
| | Cholinesterase Inhibitors | 4 | 2021 | 25 | 0.930 |
Why?
| | Hypoxia-Ischemia, Brain | 3 | 2010 | 26 | 0.910 |
Why?
| | Consciousness | 1 | 2023 | 20 | 0.900 |
Why?
| | Nervous System Diseases | 7 | 2020 | 253 | 0.860 |
Why?
| | Receptors, Cholinergic | 4 | 2011 | 41 | 0.850 |
Why?
| | Humans | 122 | 2023 | 115587 | 0.820 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2013 | 221 | 0.810 |
Why?
| | Evoked Potentials, Auditory | 6 | 2004 | 173 | 0.760 |
Why?
| | Psychiatry | 4 | 2016 | 155 | 0.750 |
Why?
| | Forensic Psychiatry | 2 | 2013 | 25 | 0.750 |
Why?
| | Hippocampus | 9 | 2019 | 709 | 0.710 |
Why?
| | Functional Laterality | 8 | 2016 | 201 | 0.700 |
Why?
| | Antipsychotic Agents | 4 | 2015 | 183 | 0.690 |
Why?
| | Irritable Mood | 3 | 2022 | 48 | 0.680 |
Why?
| | Alcoholism | 6 | 2022 | 713 | 0.670 |
Why?
| | Memory | 6 | 2017 | 211 | 0.670 |
Why?
| | Psychomotor Performance | 5 | 2011 | 278 | 0.670 |
Why?
| | Diagnosis, Differential | 16 | 2017 | 1357 | 0.660 |
Why?
| | Autism Spectrum Disorder | 1 | 2023 | 322 | 0.650 |
Why?
| | Hallucinations | 2 | 2016 | 29 | 0.650 |
Why?
| | Psychiatric Status Rating Scales | 10 | 2015 | 485 | 0.640 |
Why?
| | Amnesia | 3 | 2023 | 42 | 0.640 |
Why?
| | Acetylcholine | 4 | 2011 | 180 | 0.640 |
Why?
| | Brain Injury, Chronic | 2 | 2013 | 21 | 0.620 |
Why?
| | Confusion | 2 | 2020 | 25 | 0.600 |
Why?
| | Severity of Illness Index | 12 | 2011 | 2578 | 0.600 |
Why?
| | Cognition | 7 | 2018 | 980 | 0.600 |
Why?
| | Cholinergic Fibers | 3 | 2011 | 18 | 0.600 |
Why?
| | Dementia | 3 | 2013 | 185 | 0.590 |
Why?
| | Adult | 48 | 2023 | 30718 | 0.590 |
Why?
| | Aphasia | 2 | 2015 | 19 | 0.580 |
Why?
| | Neurology | 2 | 2010 | 85 | 0.580 |
Why?
| | Attention | 9 | 2019 | 394 | 0.550 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 230 | 0.550 |
Why?
| | Impulsive Behavior | 2 | 2014 | 109 | 0.540 |
Why?
| | Politics | 1 | 2017 | 79 | 0.540 |
Why?
| | Capgras Syndrome | 1 | 2016 | 3 | 0.530 |
Why?
| | West Nile Fever | 2 | 2008 | 50 | 0.520 |
Why?
| | Brain Concussion | 5 | 2023 | 469 | 0.520 |
Why?
| | Dopamine Agents | 2 | 2006 | 13 | 0.510 |
Why?
| | Expert Testimony | 2 | 2013 | 55 | 0.510 |
Why?
| | Pseudobulbar Palsy | 2 | 2005 | 2 | 0.510 |
Why?
| | Male | 61 | 2021 | 55949 | 0.500 |
Why?
| | Journalism, Medical | 1 | 2015 | 6 | 0.500 |
Why?
| | Stroke Rehabilitation | 2 | 2005 | 34 | 0.490 |
Why?
| | Connectome | 3 | 2023 | 63 | 0.490 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 57 | 0.480 |
Why?
| | Recovery of Function | 5 | 2019 | 577 | 0.460 |
Why?
| | Electroencephalography | 4 | 2015 | 365 | 0.450 |
Why?
| | Psychotropic Drugs | 1 | 2014 | 54 | 0.450 |
Why?
| | Periodicals as Topic | 1 | 2016 | 183 | 0.440 |
Why?
| | Middle Aged | 37 | 2021 | 26999 | 0.440 |
Why?
| | Magnetic Resonance Imaging | 19 | 2023 | 3069 | 0.430 |
Why?
| | Indans | 1 | 2013 | 9 | 0.430 |
Why?
| | Neurotransmitter Agents | 3 | 2008 | 77 | 0.430 |
Why?
| | Mental Status Schedule | 2 | 2010 | 34 | 0.430 |
Why?
| | Behavioral Symptoms | 1 | 2013 | 40 | 0.420 |
Why?
| | Football | 1 | 2013 | 77 | 0.410 |
Why?
| | Phenylcarbamates | 2 | 2009 | 3 | 0.400 |
Why?
| | Veterans | 4 | 2023 | 1233 | 0.400 |
Why?
| | Schizophrenia | 4 | 2015 | 418 | 0.390 |
Why?
| | Piperidines | 1 | 2013 | 163 | 0.390 |
Why?
| | Surveys and Questionnaires | 5 | 2023 | 4665 | 0.370 |
Why?
| | Neuroprotective Agents | 2 | 2009 | 105 | 0.370 |
Why?
| | Diffusion Tensor Imaging | 1 | 2011 | 66 | 0.360 |
Why?
| | Frontal Lobe | 3 | 2013 | 139 | 0.360 |
Why?
| | Violence | 1 | 2013 | 202 | 0.360 |
Why?
| | Capital Punishment | 1 | 2010 | 3 | 0.350 |
Why?
| | Female | 46 | 2021 | 59913 | 0.350 |
Why?
| | Cerebral Cortex | 5 | 2019 | 386 | 0.340 |
Why?
| | Public Policy | 1 | 2010 | 61 | 0.340 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 61 | 0.330 |
Why?
| | Post-Concussion Syndrome | 3 | 2013 | 155 | 0.330 |
Why?
| | Treatment Outcome | 13 | 2022 | 9159 | 0.320 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2015 | 100 | 0.320 |
Why?
| | Reflex | 1 | 2009 | 65 | 0.320 |
Why?
| | Alzheimer Disease | 3 | 2011 | 438 | 0.310 |
Why?
| | Geriatric Assessment | 1 | 2010 | 176 | 0.310 |
Why?
| | Depression | 4 | 2009 | 1145 | 0.310 |
Why?
| | Insanity Defense | 1 | 2008 | 12 | 0.310 |
Why?
| | Neuroanatomy | 2 | 2023 | 10 | 0.300 |
Why?
| | Amygdala | 3 | 2018 | 179 | 0.300 |
Why?
| | Injury Severity Score | 5 | 2019 | 458 | 0.300 |
Why?
| | Dibenzothiazepines | 1 | 2007 | 17 | 0.300 |
Why?
| | Central Nervous System Stimulants | 4 | 2016 | 140 | 0.300 |
Why?
| | Delirium | 1 | 2008 | 66 | 0.300 |
Why?
| | Crime | 1 | 2008 | 59 | 0.300 |
Why?
| | Rivastigmine | 3 | 2021 | 4 | 0.290 |
Why?
| | Stroke | 5 | 2015 | 1016 | 0.290 |
Why?
| | Affect | 4 | 2008 | 244 | 0.290 |
Why?
| | Double-Blind Method | 5 | 2022 | 1660 | 0.280 |
Why?
| | Executive Function | 2 | 2016 | 373 | 0.280 |
Why?
| | Suicide | 1 | 2013 | 501 | 0.280 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 941 | 0.270 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 465 | 0.270 |
Why?
| | Adrenergic Agents | 1 | 2006 | 5 | 0.270 |
Why?
| | Hiccup | 1 | 2006 | 2 | 0.270 |
Why?
| | Behavioral Sciences | 1 | 2006 | 9 | 0.270 |
Why?
| | Methylphenidate | 3 | 2016 | 36 | 0.270 |
Why?
| | Military Personnel | 2 | 2023 | 525 | 0.260 |
Why?
| | Hemiplegia | 1 | 2005 | 19 | 0.260 |
Why?
| | Neuropsychology | 1 | 2006 | 32 | 0.260 |
Why?
| | Physical Therapy Modalities | 2 | 2005 | 269 | 0.250 |
Why?
| | Paresis | 1 | 2005 | 28 | 0.250 |
Why?
| | Indians, North American | 2 | 2010 | 584 | 0.250 |
Why?
| | Amantadine | 1 | 2004 | 7 | 0.250 |
Why?
| | Specialization | 1 | 2006 | 117 | 0.250 |
Why?
| | Psychosurgery | 1 | 2004 | 5 | 0.240 |
Why?
| | Motor Skills | 1 | 2005 | 80 | 0.240 |
Why?
| | Neurologic Examination | 5 | 2008 | 116 | 0.240 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2004 | 20 | 0.240 |
Why?
| | Upper Extremity | 1 | 2005 | 84 | 0.240 |
Why?
| | Critical Care | 1 | 2008 | 477 | 0.240 |
Why?
| | Hospital Mortality | 1 | 2008 | 779 | 0.240 |
Why?
| | Disability Evaluation | 3 | 2019 | 271 | 0.230 |
Why?
| | Neuroimaging | 5 | 2019 | 247 | 0.230 |
Why?
| | Comorbidity | 3 | 2014 | 1473 | 0.230 |
Why?
| | Stress Disorders, Post-Traumatic | 4 | 2021 | 758 | 0.230 |
Why?
| | Valproic Acid | 2 | 2022 | 43 | 0.220 |
Why?
| | Predictive Value of Tests | 5 | 2019 | 1805 | 0.210 |
Why?
| | Research Design | 1 | 2009 | 946 | 0.210 |
Why?
| | Analysis of Variance | 5 | 2007 | 1227 | 0.200 |
Why?
| | Aged | 13 | 2019 | 19251 | 0.200 |
Why?
| | Delusions | 2 | 2015 | 9 | 0.200 |
Why?
| | Emotions | 3 | 2019 | 477 | 0.200 |
Why?
| | Magnetoencephalography | 5 | 2011 | 104 | 0.200 |
Why?
| | Exercise Therapy | 1 | 2005 | 351 | 0.200 |
Why?
| | Thalamus | 2 | 2018 | 78 | 0.190 |
Why?
| | Regression Analysis | 5 | 2013 | 959 | 0.190 |
Why?
| | Central Nervous System Agents | 1 | 2000 | 5 | 0.190 |
Why?
| | Dominance, Cerebral | 1 | 2000 | 50 | 0.190 |
Why?
| | Electroconvulsive Therapy | 2 | 2014 | 7 | 0.180 |
Why?
| | Mental Status and Dementia Tests | 1 | 2020 | 20 | 0.180 |
Why?
| | Conversion Disorder | 1 | 2020 | 9 | 0.170 |
Why?
| | Rehabilitation Centers | 1 | 2020 | 32 | 0.170 |
Why?
| | Acceptance and Commitment Therapy | 1 | 2020 | 27 | 0.170 |
Why?
| | Hospitalization | 1 | 2008 | 1765 | 0.170 |
Why?
| | Physical and Rehabilitation Medicine | 1 | 2020 | 28 | 0.170 |
Why?
| | Prisoners | 1 | 2021 | 126 | 0.170 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2019 | 10 | 0.170 |
Why?
| | Glasgow Coma Scale | 2 | 2011 | 144 | 0.170 |
Why?
| | Brain Diseases | 1 | 2000 | 127 | 0.170 |
Why?
| | Chronic Traumatic Encephalopathy | 1 | 2019 | 14 | 0.170 |
Why?
| | Sensory Thresholds | 1 | 1999 | 28 | 0.160 |
Why?
| | Prospective Studies | 6 | 2017 | 6264 | 0.160 |
Why?
| | Substance-Related Disorders | 2 | 2020 | 950 | 0.160 |
Why?
| | Habenula | 1 | 2018 | 11 | 0.160 |
Why?
| | Facial Expression | 1 | 2019 | 60 | 0.160 |
Why?
| | Suicidal Ideation | 2 | 2023 | 399 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 5 | 2013 | 482 | 0.160 |
Why?
| | Lithium Compounds | 1 | 2018 | 9 | 0.150 |
Why?
| | Spatial Memory | 1 | 2017 | 17 | 0.150 |
Why?
| | Sertraline | 2 | 2009 | 26 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2011 | 6417 | 0.140 |
Why?
| | Anxiety Disorders | 2 | 2014 | 310 | 0.140 |
Why?
| | Biomechanical Phenomena | 2 | 2011 | 677 | 0.140 |
Why?
| | Glutamic Acid | 2 | 2011 | 213 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 279 | 0.140 |
Why?
| | Prognosis | 4 | 2019 | 3339 | 0.140 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 261 | 0.140 |
Why?
| | Choline | 4 | 2013 | 108 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2019 | 2800 | 0.140 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 18 | 0.130 |
Why?
| | Encephalitis | 1 | 2017 | 127 | 0.130 |
Why?
| | Suicide, Attempted | 1 | 2018 | 316 | 0.130 |
Why?
| | Aspartic Acid | 3 | 2011 | 79 | 0.130 |
Why?
| | Evidence-Based Medicine | 2 | 2011 | 684 | 0.130 |
Why?
| | Length of Stay | 2 | 2011 | 958 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2011 | 3022 | 0.120 |
Why?
| | Behavior, Animal | 1 | 2017 | 472 | 0.120 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 85 | 0.120 |
Why?
| | Creatine | 2 | 2011 | 51 | 0.110 |
Why?
| | Terminology as Topic | 2 | 2008 | 186 | 0.110 |
Why?
| | Retrospective Studies | 7 | 2019 | 12608 | 0.110 |
Why?
| | White Matter | 1 | 2015 | 103 | 0.110 |
Why?
| | Leukoencephalopathies | 1 | 2013 | 21 | 0.110 |
Why?
| | Volition | 2 | 2006 | 29 | 0.110 |
Why?
| | Range of Motion, Articular | 2 | 2005 | 354 | 0.110 |
Why?
| | Inpatients | 2 | 2018 | 380 | 0.100 |
Why?
| | Hyperbaric Oxygenation | 1 | 2012 | 37 | 0.100 |
Why?
| | Blast Injuries | 1 | 2012 | 43 | 0.100 |
Why?
| | Phenotype | 1 | 1999 | 2829 | 0.100 |
Why?
| | Anxiety | 1 | 2017 | 853 | 0.100 |
Why?
| | Delphi Technique | 2 | 2023 | 164 | 0.100 |
Why?
| | Neurobiology | 1 | 2011 | 17 | 0.090 |
Why?
| | Multiple Sclerosis | 2 | 2007 | 380 | 0.090 |
Why?
| | Forensic Medicine | 1 | 2011 | 16 | 0.090 |
Why?
| | Cohort Studies | 4 | 2023 | 4944 | 0.090 |
Why?
| | United States | 6 | 2023 | 12295 | 0.090 |
Why?
| | Risk Assessment | 3 | 2011 | 2987 | 0.090 |
Why?
| | Antidepressive Agents | 2 | 2018 | 195 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 111 | 0.090 |
Why?
| | Schizophrenic Psychology | 2 | 2002 | 86 | 0.090 |
Why?
| | Rest | 1 | 2011 | 100 | 0.090 |
Why?
| | Economics | 1 | 2010 | 8 | 0.090 |
Why?
| | Supreme Court Decisions | 1 | 2010 | 10 | 0.090 |
Why?
| | Language Disorders | 1 | 2010 | 32 | 0.090 |
Why?
| | Adolescent | 6 | 2019 | 17889 | 0.090 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 31 | 0.080 |
Why?
| | Consensus | 2 | 2023 | 532 | 0.080 |
Why?
| | Animals | 7 | 2017 | 32102 | 0.080 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 29 | 0.080 |
Why?
| | Citalopram | 1 | 2009 | 27 | 0.080 |
Why?
| | Atrophy | 2 | 2007 | 152 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 686 | 0.080 |
Why?
| | International Classification of Diseases | 1 | 2010 | 118 | 0.080 |
Why?
| | Capsules | 1 | 2009 | 36 | 0.080 |
Why?
| | Time | 1 | 2009 | 72 | 0.080 |
Why?
| | Young Adult | 5 | 2019 | 10470 | 0.080 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 182 | 0.080 |
Why?
| | Prevalence | 2 | 2021 | 2264 | 0.080 |
Why?
| | Medical Records | 1 | 2009 | 157 | 0.080 |
Why?
| | Neurochemistry | 1 | 2008 | 5 | 0.080 |
Why?
| | Antibodies | 1 | 2010 | 374 | 0.080 |
Why?
| | Dissociative Disorders | 1 | 2008 | 22 | 0.080 |
Why?
| | Presenilin-2 | 1 | 2007 | 3 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2007 | 22 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2392 | 0.080 |
Why?
| | Presenilin-1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 342 | 0.070 |
Why?
| | Pilot Projects | 2 | 2010 | 1377 | 0.070 |
Why?
| | Research | 1 | 2011 | 396 | 0.070 |
Why?
| | Incidence | 2 | 2011 | 2335 | 0.070 |
Why?
| | Receptors, Neurotransmitter | 1 | 2007 | 15 | 0.070 |
Why?
| | Motor Activity | 2 | 2017 | 633 | 0.070 |
Why?
| | Wasting Disease, Chronic | 1 | 2007 | 18 | 0.070 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 32 | 0.070 |
Why?
| | Intelligence Tests | 1 | 2007 | 59 | 0.070 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 9 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 724 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1718 | 0.070 |
Why?
| | Disease Management | 1 | 2010 | 563 | 0.070 |
Why?
| | Gyrus Cinguli | 2 | 2023 | 69 | 0.070 |
Why?
| | Expressed Emotion | 1 | 2006 | 18 | 0.070 |
Why?
| | Accidents, Traffic | 1 | 2007 | 170 | 0.070 |
Why?
| | Lithium Carbonate | 1 | 2006 | 6 | 0.070 |
Why?
| | Sex Factors | 2 | 2003 | 1736 | 0.070 |
Why?
| | Disease Progression | 2 | 2011 | 2418 | 0.070 |
Why?
| | Biogenic Amines | 1 | 2006 | 4 | 0.070 |
Why?
| | Demography | 1 | 2007 | 261 | 0.070 |
Why?
| | Illusions | 1 | 2006 | 13 | 0.070 |
Why?
| | Age Factors | 2 | 2019 | 2907 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 114 | 0.060 |
Why?
| | Education | 1 | 2006 | 99 | 0.060 |
Why?
| | Health Surveys | 1 | 2007 | 446 | 0.060 |
Why?
| | Patient Selection | 1 | 2009 | 654 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2006 | 115 | 0.060 |
Why?
| | Restraint, Physical | 1 | 2005 | 92 | 0.060 |
Why?
| | Diazepam | 1 | 2004 | 27 | 0.060 |
Why?
| | Hydrocortisone | 1 | 2006 | 273 | 0.060 |
Why?
| | Confidence Intervals | 1 | 2005 | 309 | 0.060 |
Why?
| | History, Ancient | 1 | 2004 | 51 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2010 | 646 | 0.060 |
Why?
| | History, 19th Century | 1 | 2004 | 56 | 0.060 |
Why?
| | Probability | 1 | 2005 | 294 | 0.060 |
Why?
| | Narcotics | 1 | 2004 | 45 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 123 | 0.060 |
Why?
| | Arm | 1 | 2005 | 105 | 0.060 |
Why?
| | Age of Onset | 1 | 2006 | 450 | 0.060 |
Why?
| | Nerve Net | 1 | 2007 | 228 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2416 | 0.060 |
Why?
| | Demyelinating Diseases | 1 | 2004 | 75 | 0.060 |
Why?
| | Physostigmine | 1 | 2004 | 10 | 0.060 |
Why?
| | Autoantibodies | 1 | 2011 | 1360 | 0.060 |
Why?
| | Time Factors | 2 | 2007 | 6165 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2005 | 151 | 0.060 |
Why?
| | Cytokines | 1 | 2011 | 1853 | 0.060 |
Why?
| | Methadone | 1 | 2004 | 77 | 0.060 |
Why?
| | North America | 1 | 2004 | 261 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 2004 | 134 | 0.060 |
Why?
| | History, 20th Century | 1 | 2004 | 273 | 0.060 |
Why?
| | Cooperative Behavior | 2 | 2006 | 390 | 0.060 |
Why?
| | Electrophysiology | 1 | 2003 | 202 | 0.050 |
Why?
| | Akinetic Mutism | 1 | 2003 | 2 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2005 | 181 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2023 | 99 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 241 | 0.050 |
Why?
| | Cerebral Arterial Diseases | 1 | 2003 | 42 | 0.050 |
Why?
| | Physician's Role | 1 | 2004 | 199 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 596 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2004 | 196 | 0.050 |
Why?
| | Depressive Disorder | 1 | 2005 | 336 | 0.050 |
Why?
| | Auditory Cortex | 1 | 2002 | 41 | 0.050 |
Why?
| | Geriatric Psychiatry | 1 | 2002 | 11 | 0.050 |
Why?
| | Psychotherapy | 1 | 2003 | 149 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2005 | 478 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3580 | 0.050 |
Why?
| | Acute Disease | 1 | 2004 | 914 | 0.050 |
Why?
| | Unconsciousness | 1 | 2001 | 18 | 0.050 |
Why?
| | Chronic Disease | 2 | 2005 | 1598 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2002 | 70 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2499 | 0.050 |
Why?
| | Transdermal Patch | 1 | 2021 | 15 | 0.050 |
Why?
| | Myelinolysis, Central Pontine | 1 | 2000 | 2 | 0.050 |
Why?
| | Psychomotor Disorders | 1 | 2000 | 17 | 0.050 |
Why?
| | Societies, Medical | 2 | 2020 | 684 | 0.050 |
Why?
| | Prefrontal Cortex | 1 | 2023 | 267 | 0.040 |
Why?
| | Epilepsies, Partial | 1 | 2000 | 31 | 0.040 |
Why?
| | Rehabilitation Research | 1 | 2020 | 6 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 332 | 0.040 |
Why?
| | Syndrome | 1 | 2000 | 339 | 0.040 |
Why?
| | Curriculum | 1 | 2006 | 852 | 0.040 |
Why?
| | Magnetics | 1 | 1999 | 38 | 0.040 |
Why?
| | Corpus Striatum | 1 | 2000 | 124 | 0.040 |
Why?
| | Glasgow Outcome Scale | 1 | 2019 | 6 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1127 | 0.040 |
Why?
| | Happiness | 1 | 2019 | 22 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2000 | 137 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 88 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 123 | 0.040 |
Why?
| | Temporal Lobe | 1 | 2019 | 80 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 152 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4440 | 0.040 |
Why?
| | Evoked Potentials | 1 | 2019 | 110 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 744 | 0.040 |
Why?
| | Reaction Time | 1 | 2000 | 373 | 0.040 |
Why?
| | Mass Screening | 1 | 2005 | 1024 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 434 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2004 | 607 | 0.040 |
Why?
| | Gliosis | 1 | 2017 | 30 | 0.040 |
Why?
| | Maze Learning | 1 | 2017 | 87 | 0.040 |
Why?
| | Gray Matter | 1 | 2018 | 65 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2019 | 334 | 0.040 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 220 | 0.040 |
Why?
| | Brain Chemistry | 2 | 2009 | 116 | 0.040 |
Why?
| | Fear | 1 | 2019 | 297 | 0.030 |
Why?
| | Astrocytes | 1 | 2017 | 163 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 350 | 0.030 |
Why?
| | Microglia | 1 | 2017 | 203 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2015 | 35 | 0.030 |
Why?
| | Biomarkers | 2 | 2011 | 3466 | 0.030 |
Why?
| | Academic Medical Centers | 2 | 2010 | 414 | 0.030 |
Why?
| | Software | 1 | 1999 | 541 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 952 | 0.030 |
Why?
| | Child | 2 | 2019 | 18488 | 0.030 |
Why?
| | Colorado | 3 | 2011 | 4113 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 776 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 284 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2011 | 1440 | 0.030 |
Why?
| | Risk Factors | 2 | 2004 | 8697 | 0.030 |
Why?
| | Caregivers | 1 | 2020 | 713 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2004 | 2161 | 0.030 |
Why?
| | Creatinine | 1 | 2013 | 430 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2013 | 224 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 499 | 0.020 |
Why?
| | Visual Perception | 1 | 2011 | 141 | 0.020 |
Why?
| | Neurofibrillary Tangles | 1 | 2007 | 13 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4435 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2007 | 31 | 0.020 |
Why?
| | Axons | 1 | 2009 | 179 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 68 | 0.020 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 4 | 0.020 |
Why?
| | Brain Mapping | 1 | 2011 | 521 | 0.020 |
Why?
| | Disease Reservoirs | 1 | 2007 | 19 | 0.020 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2007 | 7 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 41 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 286 | 0.020 |
Why?
| | Introns | 1 | 2007 | 226 | 0.020 |
Why?
| | Point Mutation | 1 | 2007 | 217 | 0.020 |
Why?
| | Prolactin | 1 | 2007 | 95 | 0.020 |
Why?
| | Thyrotropin | 1 | 2007 | 100 | 0.020 |
Why?
| | Antiemetics | 1 | 2006 | 32 | 0.020 |
Why?
| | Psychomotor Agitation | 1 | 2007 | 66 | 0.020 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 148 | 0.020 |
Why?
| | Mental Health Services | 1 | 2010 | 326 | 0.020 |
Why?
| | Stereotyping | 1 | 2006 | 39 | 0.020 |
Why?
| | Vomiting | 1 | 2006 | 125 | 0.020 |
Why?
| | Benzamides | 1 | 2006 | 168 | 0.020 |
Why?
| | Skull | 1 | 2006 | 117 | 0.020 |
Why?
| | Verbal Behavior | 1 | 2005 | 43 | 0.020 |
Why?
| | Mental Processes | 1 | 2005 | 33 | 0.020 |
Why?
| | Carbamazepine | 1 | 2005 | 18 | 0.020 |
Why?
| | Saliva | 1 | 2006 | 189 | 0.020 |
Why?
| | MEDLINE | 1 | 2005 | 22 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 2005 | 61 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 621 | 0.010 |
Why?
| | Central Nervous System | 1 | 2005 | 239 | 0.010 |
Why?
| | Language | 1 | 2005 | 258 | 0.010 |
Why?
| | Hospitals, Veterans | 1 | 2004 | 245 | 0.010 |
Why?
| | Radiography | 1 | 2005 | 826 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1870 | 0.010 |
Why?
| | Mice | 1 | 2017 | 15052 | 0.010 |
Why?
| | Brain Ischemia | 1 | 2005 | 298 | 0.010 |
Why?
| | Pain | 1 | 2007 | 712 | 0.010 |
Why?
| | Median Nerve | 1 | 1999 | 20 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 263 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 509 | 0.010 |
Why?
|
|
Arciniegas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|